| WB | 1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Ethylmalonyl-CoA decarboxylase, Enoyl-CoA hydratase domain-containing protein 1, Methylmalonyl-CoA decarboxylase, MMCD, ECHDC1 |
| Entrez GeneID | 55862 |
| WB Predicted band size | 33.7kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | This ECHDC1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 254-283 amino acids from the C-terminal region of human ECHDC1. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于ECHDC1抗体的3篇参考文献示例(注：以下内容为模拟虚构，仅供参考)：
1. **文献名称**：*ECHDC1 regulates hepatic fatty acid oxidation and its antibody-based detection in metabolic disorders*
**作者**：Zhang L, et al.
**摘要**：本研究利用特异性ECHDC1抗体，通过Western blot和免疫组化技术，揭示了ECHDC1在肝脏脂肪酸氧化中的关键作用，并发现其在非酒精性脂肪肝患者中表达显著下调。
2. **文献名称**：*Development and validation of a monoclonal antibody against human ECHDC1 for diagnostic applications*
**作者**：Smith J, et al.
**摘要**：报道了一种新型小鼠源ECHDC1单克隆抗体的开发，验证了其在ELISA和免疫荧光中的高特异性，为ECHDC1相关代谢疾病的临床检测提供了工具。
3. **文献名称**：*ECHDC1 deficiency exacerbates obesity-induced insulin resistance: Evidence from antibody-mediated protein localization*
**作者**：Tanaka K, et al.
**摘要**：通过ECHDC1抗体进行组织定位分析，发现ECHDC1在小鼠脂肪组织中高表达，其缺失导致肥胖模型胰岛素敏感性下降，提示其作为代谢治疗靶点的潜力。
(注：以上文献为示例性内容，实际文献需通过PubMed/Google Scholar等平台检索确认。)
The ECHDC1 (Enoyl-CoA Hydratase Domain-Containing 1) antibody is a tool used to detect and study the ECHDC1 protein, which belongs to the hydrolase enzyme family. ECHDC1 is implicated in fatty acid metabolism, particularly in the breakdown of short-chain fatty acids via its enoyl-CoA hydratase activity. This mitochondrial enzyme plays a role in lipid homeostasis, influencing pathways linked to energy production and metabolic regulation. Dysregulation of ECHDC1 has been associated with metabolic disorders, including obesity, insulin resistance, and non-alcoholic fatty liver disease (NAFLD), making it a target for metabolic disease research.
The ECHDC1 antibody is widely utilized in techniques such as Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to assess protein expression, localization, and tissue distribution. Studies employing this antibody have revealed elevated ECHDC1 levels in adipose tissue and liver under conditions of metabolic stress, suggesting its role in adaptive responses to lipid overload. Its specificity is validated through knockdown/knockout controls, ensuring reliability in experimental models.
Research using ECHDC1 antibodies has advanced understanding of its interaction with peroxisome proliferator-activated receptors (PPARs) and other regulators of lipid metabolism. Such insights highlight its potential as a biomarker or therapeutic target for metabolic syndromes. Overall, the ECHDC1 antibody serves as a critical reagent in exploring cellular lipid handling and metabolic disease mechanisms.
×
